Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 40 Ovarian Neoplasms 32 Triple Negative Breast Neoplasms 20 Prostatic Neoplasms 17 Fallopian Tube Neoplasms 16 Neoplasm Metastasis 14 Endometrial Neoplasms 10 Pancreatic Neoplasms 9 Neoplasms 9 Carcinoma, Non-Small-Cell Lung 7 Small Cell Lung Carcinoma 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Glioma 6 Stomach Neoplasms 5 Sarcoma 5 Lung Neoplasms 5 Glioblastoma 5 Squamous Cell Carcinoma of Head and Neck 4 Neuroendocrine Tumors 4 Metastatic Castration-resistant Prostate Cancer 4 Carcinoma, Ovarian Epithelial 4 Solid Tumors 3 Recurrence 3 Osteosarcoma 3 Lymphoma, Non-Hodgkin 3 Cholangiocarcinoma 3 Urinary Bladder Neoplasms 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Prostatic Neoplasms, Castration-Resistant 2

Interventions

Cisplatin 32 Gemcitabine 21 Radiotherapy, Intensity-Modulated 16 toripalimab 14 Capecitabine 11 Magnetic Resonance Spectroscopy 10 Specimen Handling 9 Radiotherapy 7 Drug Therapy 7 pembrolizumab 6 Platinum 6 Nivolumab 6 Immune Checkpoint Inhibitors 6 1,2-diaminocyclohexaneplatinum II citrate 6 Docetaxel 5 tislelizumab 4 spartalizumab 4 camrelizumab 4 sintilimab 3 anlotinib 3 Immunoglobulin G 3 Disulfides 3 Carboplatin 3 nimotuzumab 2 fludarabine 2 atezolizumab 2 Taxes 2 Radiation 2 Phantoms, Imaging 2 Ipilimumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Nasopharyngeal Carcinoma × olaparib × 1 year × Clear all

NCT04825990 2026-06-01

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡